Caligan-linked Exelixis director reports 27,532-share EXEL purchase
Rhea-AI Filing Summary
Exelixis, Inc. (EXEL)27,532 shares of common stock on 11/25/2025 at a price of $43.122 per share. After this transaction, 1,553,262 shares are reported as indirectly owned through Caligan-managed funds and accounts, while 18,176 shares are reported separately, which include 9,088 shares that will be issued upon vesting of restricted stock units to Johnson. The reporting persons state they disclaim beneficial ownership of the securities beyond any pecuniary interest and note that Caligan may be deemed a director by deputization because Johnson serves on the Exelixis board.
Positive
- None.
Negative
- None.
Insights
Analyzing...
FAQ
What insider transaction did Exelixis (EXEL) disclose in this Form 4?
The filing reports that David Johnson, a director of Exelixis, and Caligan Partners LP were involved in an open-market purchase of 27,532 shares of EXEL common stock on 11/25/2025 at $43.122 per share.
How many Exelixis (EXEL) shares does David Johnson indirectly report owning after the transaction?
Following the reported purchase, the filing states that 1,553,262 shares of EXEL common stock are beneficially owned indirectly through Caligan Partners Master Fund LP and managed accounts advised by Caligan Partners LP.
What is David Johnsons relationship to Exelixis (EXEL) and Caligan Partners?
David Johnson is listed as a director of Exelixis and is described as the Managing Partner of Caligan Partners LP and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
How many Exelixis (EXEL) shares are tied to David Johnsons restricted stock units?
The filing notes that the holdings include 9,088 shares of EXEL common stock that will be issued to David Johnson upon vesting of restricted stock units, which may then be transferred to Caligan funds and accounts.
Do the reporting persons claim full beneficial ownership of the Exelixis (EXEL) shares?
No. Each reporting person disclaims beneficial ownership of the securities reported, except to the extent of its or his pecuniary interest, and the report states it should not be deemed an admission of beneficial ownership for Section 16 or other purposes.
Why might Caligan Partners be considered a director of Exelixis (EXEL)?
The filing explains that Caligan Partners LP may be deemed to be a director by deputization of Exelixis because David Johnson, Caligans Managing Partner, currently serves on Exelixiss board of directors.